Management of Nighttime Awakenings and Obstructive Sleep Apnea Before Using Stimulant Medications

Evaluation and Diagnostic Work‑up

The National Comprehensive Cancer Network (NCCN) recommends formal polysomnography for any patient with frequent nighttime awakenings and possible obstructive sleep apnea before considering stimulating agents. 1
Polysomnography is indicated when sleep‑disordered breathing symptoms such as frequent arousals and unexplained daytime drowsiness are present. 1

According to NCCN guidelines, primary sleep disorders like OSA should be treated with CPAP or BiPAP as first‑line therapy before adding any wake‑promoting medication. 1
If polysomnography confirms OSA (apnea‑hypopnea index > 5 with symptoms or > 15 without symptoms), CPAP therapy should be initiated immediately. 1
Adequate CPAP adherence is defined as usage > 4 hours per night; only after achieving this level should residual symptoms be reassessed. 5

The American Academy of Sleep Medicine notes that bupropion has no therapeutic role in improving sleep continuity and may actually worsen insomnia. 4
Stimulant antidepressants such as bupropion can exacerbate sleep fragmentation when underlying OSA remains untreated. [5][6]

NCCN states that modafinil or armodafinil are the only FDA‑approved agents for residual excessive daytime sleepiness in patients who are adherent to CPAP therapy for OSA. [2][3]7
Modafinil, dosed 100–200 mg in the morning, is preferred over other stimulants for this indication. [2][3]7

If polysomnography rules out OSA, nighttime awakenings should first be managed with sleep‑promoting agents rather than stimulants. [1][2]4
Trazodone (25–50 mg) or low‑dose mirtazapine (7.5–15 mg) taken at bedtime are suggested for sleep maintenance, with the caveat that mirtazapine may cause weight gain. [1][2]4
Adequate total sleep duration must be achieved before considering any wake‑promoting medication for residual daytime fatigue. 7